Revance Therapeutics: Q4 Earnings Insights

Revance Therapeutics RVNC reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Revance Therapeutics beat estimated earnings by 8.82%, reporting an EPS of $-0.93 versus an estimate of $-1.02.

Revenue was up $14.82 million from the same period last year.

Last quarter the company beat on EPS by $0.05 which was followed by a 5.03% increase in the share price the next day.

Here's a look at Revance Therapeutics's past performance:

Quarter	Q3 2021	Q2 2021	Q1 2021	Q4 2020
EPS Estimate	-1.15	-1.05	-1.09	-1.24
EPS Actual	-1.10	-1.07	-1.08	-1.24
Revenue Estimate	20.29M	15.48M	10.98M	8.78M
Revenue Actual	19.75M	18.80M	13.30M	11.13M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar